Search

Your search keyword '"Günthard, Huldrych F"' showing total 1,770 results

Search Constraints

Start Over You searched for: Author "Günthard, Huldrych F" Remove constraint Author: "Günthard, Huldrych F"
1,770 results on '"Günthard, Huldrych F"'

Search Results

2. 2022 update of the drug resistance mutations in HIV-1.

3. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

4. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

5. Assessing immunogenicity barriers of the HIV-1 envelope trimer

6. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

7. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes

8. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

9. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

10. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

11. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

12. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV

13. Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

14. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

15. 2019 update of the drug resistance mutations in HIV-1.

16. Reply to Ambrosioni et al.

17. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

19. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

20. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

21. Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

22. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

24. Using viral diversity to identify HIV-1 variants under HLA-dependent selection in a systematic viral genome-wide screen.

25. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

26. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

28. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

29. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

30. Cohort Profile: The Zurich Primary HIV Infection Study

31. Phenotypic and genotypic characterization of Neisseria gonorrhoeae isolates among individuals at high risk for sexually transmitted diseases in Zurich, Switzerland

32. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

33. Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection

34. 2017 Update of the Drug Resistance Mutations in HIV-1.

35. Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics

36. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV.

37. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV.

39. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

40. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes

41. T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C

42. Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1

43. 2015 Update of the Drug Resistance Mutations in HIV-1.

44. Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization

46. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity

47. Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals

48. Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution

49. Hepatitis delta infection among persons living with HIV in Europe

50. 2014 Update of the drug resistance mutations in HIV-1.

Catalog

Books, media, physical & digital resources